Company ProfilePremium

China Healthwise Holdings Limited

Company Profile Analysis

Ticker: 0348.HK中國智能健康控股有限公司

ESOMAR 23 Corporate BadgeISO Certifications Badge
China Healthwise Holdings Limited - Company showcase

Year Founded & Workforce

1997

70 Employees

China Healthwise Holdings Limited logo

China Healthwise Holdings Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

China Healthwise Holdings Limited Overview

China Healthwise is a Hong Kong micro-cap investment holding company whose only meaningful operating asset is Nam Pei Hong Sum Yung Drugs Company Limited, a traditional "Sum Yung" (參茸, ginseng and deer-antler tonics) and premium dried-seafood retailer trading under the Nam Pei Hong (南北行) brand since 1977. The Chinese health products segment generated HK$99.2 million of the group's HK$99.6 million FY2025 revenue through nine retail shops, direct sales events, wholesale and online channels including HKTVmall and a Tmall Global flagship. Two adjunct segments — a legacy money-lending book (HK$305.7 million gross, ~97% credit-impaired) and a listed-equity portfolio — have driven most of the group's volatility and cumulative losses of over HK$330 million since FY2021. The company is in capital deficiency (net liabilities HK$50.1 million at 30 June 2026), carries a going-concern material uncertainty, and faces HK$72.3 million of bond principal maturing on 30 December 2026. It is effectively a distressed-balance-sheet situation wrapped around a heritage consumer brand.


Company's own description (FY2024 results announcement / FY2025 annual report)

The Company describes itself as "an investment holding company and principally engaged in investment in financial instruments", with subsidiaries "principally engaged in sale of Chinese health products, money lending business and investment in financial instruments." The Chinese health products business "engaged in the sales of Chinese and other pharmaceutical products, health products, ginseng and dried seafood products to wholesaler and retailer," with Nam Pei Hong Sum Yung Drugs Company Limited trading and retailing Sum Yung and dried seafood products since 1977 under a brand the Company states is "highly recognised in Hong Kong and Southern Mainland China." (Source: FY2024 annual results announcement, 31 March 2025; repeated verbatim in H1 2026 interim results, 27 August 2026.)

Independent characterisation

In substance China Healthwise is three unrelated activities held together by a common controlling-influence shareholder group (Eternity Investment Limited and its nominated directors):

  1. A heritage specialty retailer (≈99.6% of FY2025 revenue). Nam Pei Hong sells high-value traditional Chinese tonic products — cordyceps sinensis, Korean and American ginseng, pilose antler, bird's nest, fish maw, sea cucumber, dried scallops, dendrobium — plus a growing range of convenient packaged health foods. It is a merchandising and sourcing business, not a manufacturer: the Company reports no production facilities and no R&D. Gross margin on goods is a stable low-30s percent (derived: 30.7%–34.0% across FY2021–H1 2026). Sales are seasonal, peaking around winter and Chinese New Year.

  2. A run-off consumer/commercial money-lending book. The licensed money-lending subsidiary has written no new loans to new customers since FY2023; of eleven loans outstanding at 30 June 2026, nine (HK$296.7 million gross) are stage 3 credit-impaired and fully provided. The live book (HK$9.0 million) is dominated by a revolving facility to the ultimate holding company of the substantial shareholder.

  3. A proprietary listed-equity portfolio. Financial assets at fair value through profit or loss fell from HK$54.0 million (31 Dec 2025) to HK$14.1 million (30 Jun 2026) after forced and voluntary disposals; current holdings are Ocean Line Port Development (8502.HK) and Yunfeng Financial (0376.HK). Realised gains/losses on disposals are booked within revenue, which distorts reported top line and gross margin.

Business and revenue model

Revenue typeSegmentRecognitionFY2025 share of revenue
Product sales (retail, direct-sales events, wholesale, internet)Chinese health productsPoint in time (HKFRS 15)≈99.6%
Interest incomeMoney lendingEffective interest (HKFRS 9)≈0.6%
Dividends and realised gains/losses on disposal of equitiesInvestment in financial instrumentsHKFRS 9≈-0.3% (net realised loss)

There is no subscription, licensing or service revenue. Value-chain position: downstream importer–wholesaler–retailer, with management emphasising "overseas direct sourcing" to compress procurement cost (FY2024 and H1 2026 MD&A).

Customers and end-markets

Chinese health products channel (HKD Mn)FY2021FY2022
Retail shops66.0473.72
Direct sales events33.9841.17
Internet12.6012.47
Wholesale1.581.01
Total Chinese health products114.20128.38

Customers are predominantly Hong Kong retail consumers (older, gift-giving and health-conscious households), event-based buyers at expos and festivals, corporate/institutional buyers (charities, banks and insurers via staff-purchase programmes), wholesalers, and online buyers (HKTVmall; Tmall Global for Mainland cross-border). No single customer contributed ≥10% of revenue in any year FY2021–H1 2026. End-markets: Hong Kong traditional Chinese medicine (TCM) and tonic retail, premium dried seafood, functional/health foods.

Sales-channel mix is disclosed only for FY2021–FY2022:

Source: FY2022 annual results announcement, note 3. Later years: not disclosed in results announcements reviewed.

Strategy

Stated strategic themes (FY2024 annual results, H1 2026 interim)

Defend the core retail franchise: under the motto "genuine goods at fair prices, treating all customers honestly", leveraging overseas direct sourcing to keep prices competitive.

Pivot product mix to convenient ready-to-eat health products: for younger consumers, aligned with the national "medicine-food homology" (藥食同源) wellness direction.

Channel diversification: HKTVmall live-streaming, Xiaohongshu storefront with Weimob, corporate staff-purchase programmes with banks and insurers, department-store and supermarket collaborations (Sogo, YATA), OpenRice activities.

Technology and CRM: upgrade membership/CRM system; apply AI in marketing to raise repurchase rates and store revisit frequency.

Cost control: shop-level cost discipline, staff training, G&A reductions.

Money lending: no new lending; recovery via settlement, legal action, collateral enforcement; stricter credit policy.

Investments: adjust portfolio, realise equities into cash "as and when appropriate".

Business portfolio management: "actively looking for business opportunities to diversify the revenue sources" via investments or acquisitions.

Liquidity plan (going-concern note): collect loan receivables; realise FVTPL assets; cost savings; negotiate renewal of bonds and borrowings with the bondholder and finance company.

Initiatives in the last 24 months

InitiativeAnnouncedStatus at Oct 2026
MAME LAB partnership (prenatal/postnatal products)Mar 2025Status not updated in H1 2026 filing
Xiaohongshu launch with WeimobMar 2025Not confirmed as launched
CRM membership upgradeMar 2025In progress
Corporate staff-purchase channel expansionAug 2026Planned
AI-assisted marketingAug 2026Planned
2024 Bond restructuringAug–Dec 2024Completed 31 Dec 2024; bonds due 30 Dec 2026
New Share Option SchemeAug 2024Adopted; no grants
Equity subscription (HK$10.8 M)Aug 2026Completed 27 Aug 2026
5:1 share consolidationAug 2026Effective 22 Sep 2026
Investment policy formalisationAnnual Report 2025Adopted

Medium-term targets and guidance

No quantitative revenue, margin or return targets have been published. The Company does not issue earnings guidance; it issues Listing Rule 13.09 profit alerts (e.g., positive alert for H1 2025). ESG/sustainability targets: not publicly disclosed in the sources reviewed.

Products & Services

Chinese health products segment (brand: Nam Pei Hong 南北行)

Product / categoryDescription and useTarget customerLatest disclosed trendSource
Cordyceps sinensis (冬蟲夏草)Premium caterpillar-fungus tonic; respiratory and vitality tonic in TCMAffluent health-conscious, gift buyersFY2024 sales declined (range 10%–34% across high-end lines)FY2024 MD&A
Wild cordyceps sinensis (野生冬蟲夏草)Top-grade wild-harvested variantHigh-endH1 2026 growth 4%–16% (group of growth lines)H1 2026 MD&A
Ginseng (人參) — generalRange of ginseng roots/slicesMass-affluent, elderlyFY2024 declineFY2024 MD&A
Korean ginseng (高麗參)Red ginseng rootsHigh-end, giftingH1 2026 decline (6%–30% range)H1 2026 MD&A
American ginseng (花旗參)Cooling tonic, slices and whole rootsMass-affluentH1 2026 declineH1 2026 MD&A
Pilose antler (鹿茸)Deer-antler tonic (core "Sum Yung" category)Older consumersH1 2026 decline; affected by Mainland customs controls on carrying high-end productsH1 2026 MD&A
Dendrobium (石斛)Orchid-stem yin tonicHealth-consciousH1 2026 declineH1 2026 MD&A; FY2022 promotion focus
Tianqi (田七)Notoginseng; circulation tonicElderlyPromotion focus FY2022FY2022 MD&A
Bird's nest (燕窩)Edible swiftlet nestWomen, giftingFY2024 decline; H1 2026 growthFY2024, H1 2026 MD&A
Fish maw (花膠)Dried swim bladder, collagen-richGifting, festive cookingFY2024 and H1 2026 declineMD&A
Dried scallops (元貝)Premium dried seafoodFestive cookingFY2024 declineFY2024 MD&A
Sea cucumber (海參)Dried sea cucumberFestive and tonicFY2024 sales +28%; H1 2026 growthMD&A
Japanese stichopus (日本刺參)Premium Japanese spiky sea cucumberHigh-endH1 2026 growthH1 2026 MD&A
Tai Chi Ginseng Fruit (太極蔘正果)Ready-to-eat ginseng confectionYounger / conveniencePromotion focus 2025FY2024 MD&A
Collagen Jelly (膠原果凍)Ready-to-eat beauty jellyYounger womenPromotion focus 2025FY2024 MD&A
Pure Sea Cucumber Essence Capsules (純海參精華膠囊)Supplement capsuleHealth-consciousPromotion focus 2025FY2024 MD&A
Probiotics F+ (益生菌F+)Probiotic supplementConveniencePromotion focus 2025FY2024 MD&A
Platycodon throat lozenges (桔梗順氣潤喉寶)Herbal throat lozengeMass marketPromotion focus 2025FY2024 MD&A
Herbal teas / health flower teas (養生保健花茶)Packaged teasMass marketStable sales H1 2026MD&A
Canned Premium Goji Berries (特級貢杞皇)Packaged dried gojiConvenienceStable H1 2026H1 2026 MD&A
Premium Peach Gum (特級桃膠)Packaged dessert/beauty ingredientConvenienceStable H1 2026H1 2026 MD&A
Premium Snow Lotus Seed (特級雪蓮子)Packaged dessert ingredientConvenienceStable H1 2026H1 2026 MD&A
Ginseng powder, energy drink, probiotics capsules, ganoderma capsulesConvenience health productsBusy urban consumersListed FY2022FY2022 MD&A
Anti-epidemic tea bags, nutrition stew series, gift hampersCorporate/institutional ordersCharities, institutionsFY2022FY2022 MD&A
Seasonal health product portfoliosSeasonal bundles and promotionsAllOngoingFY2024 MD&A
Prenatal/postnatal maternal health products (planned)Via MAME LAB postpartum-care centre partnershipMothersAnnounced plan 2025FY2024 MD&A

Pricing is not publicly disclosed in filings; all products are retail-priced per weight/grade or per package.

Channels and platforms

ChannelDetailStatus
Nam Pei Hong retail shops10 (end-2021 to end-2024) → 9 (end-2025 and 30 Jun 2026); locations not itemised in announcementsOperating; loss-making shops impaired
Direct-sales eventsBrands and Products Expo (工展會), food festivals, large-scale shopping events; Sogo and YATA VIP DaysOperating
HKTVmallOnline marketplace sales and live-streamingOperating; FY2022 HKTVmall turnover +20%
Tmall Global "Nam Pei Hong Overseas Flagship Shop"Cross-border e-commerce to MainlandLaunched 2022
Xiaohongshu (小紅書) via Weimob (微盟)Social-commerce storefrontAnnounced as forthcoming (FY2024 results); launch not confirmed in later filings
OpenRice platform activities; Facebook, YouTube shortsDigital marketingOperating (H1 2026)
Corporate staff-purchase programmes (banks, insurers)B2B2C channelPlanned expansion (H1 2026)
CRM / membership systemUpgrade announced; AI-driven marketing to raise repurchaseIn progress

Money lending segment

Unsecured, fixed-rate loans of 8%–13% p.a. (8%–15% in FY2021–FY2022). No new loans granted to new customers since FY2023. The only active facility is a HK$9.0 million revolving loan to the ultimate holding company of a substantial shareholder (Eternity group), rate revised to 10% fixed from March 2026, maturity March 2027.

Investment in financial instruments segment

Listed equity holdings at 30 June 2026: Ocean Line Port Development Ltd (8502.HK) — 31,588,000 shares, 3.95% stake, fair value HK$9.79 M; Yunfeng Financial Group (0376.HK) — 2,634,000 shares, 0.06%, fair value HK$4.24 M. Previously held Huanxi Media Group (1003.HK; 19.65 M shares, fair value HK$9.14 M at end-2024), disposed during 2025–H1 2026 (exact timing not disclosed). The FY2025 annual report sets an investment policy limiting single investments to 10% of total assets, non-Hong Kong assets to 10% of the portfolio, prohibiting commodity derivatives and day trading, and benchmarking returns against the 12-month HKD time-deposit rate.

Financial Narrative

Income statement: notes and sources

Notes: EBIT = pre-tax income + finance costs (derived). EBITDA = EBIT + depreciation of PPE and right-of-use assets (FY2021 4.20; FY2022 3.30; FY2023 5.62; FY2024 7.17) (derived; IFRS 16 basis, includes lease depreciation). FY2025 EPS derived (HK$2.61 M / 770.48 M shares). FY2025 pre-tax income, tax and other-income total were not available in the sources reviewed; a vendor (MarketInOut) reports FY2025 EBITDA of HK$10.54 M, which is not reconciled to filings and is not used here. Sources: annual results announcements FY2022 (FY2021–22), FY2024 (FY2023–24); FY2025 results summary (Bulletin Express, 27 Mar 2026).

Margins and growth

Revenue CAGR FY2021–FY2025: -12.5% (group, derived); -3.5% (Chinese health products, derived). FY2021 growth uses FY2020 revenue of HK$137.85 M (vendor data).

Commentary. Reported gross margin is not a meaningful operating indicator because realised investment gains and interest income are booked in revenue with no associated cost of sales; the collapse from 53.5% (FY2021) to 33.6% (FY2025) is almost entirely mix — the disappearance of HK$56 M of high-margin financial revenue. The goods-only gross margin has in fact been stable to slightly improving at 31%–34%, reflecting direct overseas sourcing and a mix shift toward sea cucumber and packaged products. The principal profit drivers each year were (i) ECL charges on the loan book (HK$102.6 M FY2021, HK$107.5 M FY2023), (ii) fair-value swings on equities, and (iii) from FY2025, rising finance costs after the 2024 bond restructuring (effective interest 15% p.a. on the bond liability components). Underlying operating expenses have been cut materially: G&A fell 44% from FY2022 to FY2025 (HK$38.3 M → HK$21.6 M), driven by lower directors' emoluments (HK$20.2 M FY2022 → HK$9.1 M FY2024). The FY2025 near-breakeven (HK$2.6 M loss) was flattered by a HK$24.6 M unrealised fair-value gain that partly reversed in H1 2026 (HK$11.7 M realised loss on disposal plus HK$4.7 M fair-value loss).

Balance sheet

Debt composition: FY2021 borrowings 12.04 + 2018 CBs 72.30; FY2022 borrowings 31.26 (current) + CBs 71.04 (non-current); FY2023 borrowings 28.72 + CBs 72.24 (both current); FY2024 borrowings 32.57 (current) + CBs 14.30 + straight bonds 49.00 (non-current); FY2025 borrowings 31.43 + CBs 15.46 + bonds 52.00 (all current). Net debt derived. Source: annual results FY2022, FY2024; H1 2026 interim (31 Dec 2025 comparatives).

Latest interim balance sheet (30 June 2026)

Post-balance-sheet: HK$10.8 M gross subscription proceeds received 27 Aug 2026, earmarked for working capital and repayment of current debt.

Cash flow

Change in cash derived from year-end balances. The Company confirmed no repurchases of its listed securities in FY2022, FY2024 and H1 2026.

Ratios

All derived from reported figures. Blank ROE/D-E cells: equity negative (FY2024–FY2025) or prior-year base unavailable (FY2021). Net debt/EBITDA not meaningful (negative EBITDA). Invested capital = equity + debt + leases − cash.

Commentary. The balance sheet has moved from HK$193 M of equity (FY2021) to a HK$50 M capital deficiency (H1 2026) in 4.5 years. Debt has been essentially flat at ~HK$96–102 M throughout — the problem is the asset side: the loan book that was supposed to service the 2018 CBs defaulted. The restructuring at end-2024 merely re-termed the CB principal into two-year paper now maturing 30 December 2026, and the H1 2026 forced deleveraging of margin loans (HK$15.6 M → HK$2.4 M) was funded by selling equities at a HK$11.7 M realised loss. Inventory days of 220–280 are long but typical for dried tonics with seasonal stocking; the cash conversion cycle has improved through tighter receivables. Interest coverage is negative every year; even the retail operation's segment loss excludes HK$5 M of unallocated bond interest per half-year.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentContentsKey entityStatus

Chinese health products

Retail, direct-sales-event, wholesale and online sale of Sum Yung, dried seafood, Chinese and other pharmaceutical and health products

Nam Pei Hong Sum Yung Drugs Company Limited

Core, operating

Money lending business

Unsecured fixed-rate loans (8%–13% p.a.) under Hong Kong Money Lenders Ordinance licence

Money-lending subsidiary (name not disclosed in announcements reviewed)

Run-off / recovery

Investment in financial instruments

Proprietary investment in Hong Kong listed (and minor unlisted) equities

Investment subsidiaries

Shrinking; used as liquidity source

Segment revenue (HKD Mn)

Segment revenue (HKD Mn)FY2021FY2022FY2023FY2024FY2025

Chinese health products

114.20128.38129.52112.8399.20

Money lending

22.2914.6310.661.130.61

Investment in financial instruments

33.59-0.956.14-0.39-0.25

Total revenue

170.08142.06146.32113.5899.56

Revenue by Segment

Segment PBT (HKD Mn)FY2021FY2022FY2023FY2024FY2025

Chinese health products

-8.871.893.19-6.05-7.48

Money lending

-97.83-30.02-115.86-10.16-1.43

Investment in financial instruments

16.91-17.75-5.68-6.4122.80

Reportable segment total

-89.79-45.88-118.34-22.6213.89

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Segment Margins & Growth (%) and Revenue by Segment (%)

MetricFY2021FY2022FY2023FY2024FY2025

Chinese health products PBT margin (%)

-7.81.52.5-5.4-7.5

Chinese health products revenue YoY (%)

—12.40.9-12.9-12.1

Chinese health products share of revenue (%)

67.190.488.599.399.6

Chinese health products goods gross margin (%)

30.730.833.632.433.4

Money lending revenue YoY (%)

—-34.4-27.1-89.4-46.0

Revenue by Segment (Half-Yearly)

Segment (HKD Mn)H1 2025 revenueH1 2026 revenueH1 2025 PBTH1 2026 PBT

Chinese health products

50.9847.90-4.40-3.06

Money lending

0.320.300.87-2.34

Investment in financial instruments

-0.24-11.7411.37-16.71

Total

51.0636.467.84-22.11

Segment assets (HKD Mn)

Segment assets (HKD Mn)FY2021FY2022FY2023FY2024FY2025

Chinese health products

84.4592.7388.6975.2162.54

Money lending

167.24137.0817.658.766.50

Investment in financial instruments

59.7557.3440.4435.5954.01

Consolidated total assets

314.10287.66149.67122.05125.21

Income Statement and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (HKD Mn)

170.08142.06146.32113.5899.56

Cost of sales (HKD Mn)

79.0988.7986.0276.2366.10

Gross profit (HKD Mn)

90.9953.2760.2937.3533.46

Other income gains and losses net (HKD Mn)

-15.15-10.10-10.17-10.48—

of which FV gain/loss on FVTPL assets (HKD Mn)

-15.30-15.33-10.34-4.1924.61

Selling and distribution expenses (HKD Mn)

-31.08-28.54-27.87-29.04-28.23

General and administrative expenses (HKD Mn)

-33.09-38.33-37.53-26.41-21.63

ECL impairment on loans net (HKD Mn)

-102.61-24.78-107.47-2.353.73

Operating income EBIT (HKD Mn)

-94.17-49.10-123.07-31.73—

EBITDA (HKD Mn)

-89.97-45.80-117.45-24.56—

Finance costs (HKD Mn)

-6.41-7.30-8.99-8.30-13.83

Pre-tax income (HKD Mn)

-100.58-56.40-132.06-40.03—

Income tax (HKD Mn)

-2.472.13-2.50-0.25—

Net income attributable (HKD Mn)

-103.05-54.27-134.56-40.28-2.61

EPS basic and diluted (HK cents)

-13.37-7.04-17.46-5.23-0.34

Dividend per share (HK cents)

00000

Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue growth YoY (%)

23.4-16.53.0-22.4-12.3

Gross margin reported (%)

53.537.541.232.933.6

Operating margin (%)

-55.4-34.6-84.1-27.9—

EBITDA margin (%)

-52.9-32.2-80.3-21.6—

Net margin (%)

-60.6-38.2-92.0-35.5-2.6

Balance Sheet

MetricFY2021FY2022FY2023FY2024FY2025

Total assets (HKD Mn)

314.10287.66149.67122.05125.21

Cash and equivalents (HKD Mn)

40.0116.8514.429.709.19

Inventories (HKD Mn)

60.7155.1256.0249.7740.11

Loan receivables net (HKD Mn)

138.57134.0517.108.576.46

FVTPL equity investments (HKD Mn)

59.3057.3140.4235.5954.01

Short-term debt (HKD Mn)

84.3431.26100.9632.5798.90

Long-term debt (HKD Mn)

071.04063.300

Total debt excl leases (HKD Mn)

84.34102.31100.9695.8798.90

Lease liabilities (HKD Mn)

6.527.607.947.877.24

Net debt excl leases (HKD Mn)

44.3385.4686.5486.1789.71

Total equity (HKD Mn)

193.06138.654.40-18.38-20.99

Goodwill and intangibles (HKD Mn)

00000

Working capital CA minus CL (HKD Mn)

82.22200.26-3.3040.25-25.06

Balance Sheet and Margin Analysis (%)

Item (HKD Mn)31 Dec 202530 Jun 2026

Total assets

125.2172.56

Cash and equivalents

9.198.55

Inventories

40.1129.91

FVTPL investments

54.0114.14

Loan receivables net

6.468.62

Margin loans from brokers (on demand, 8%–10%)

15.622.42

Other loan (12%, on demand, secured by subsidiary share charge)

15.8115.81

Convertible loan notes (2024 CBs)

15.4616.10

Bonds payable (2024 straight bonds)

52.0053.69

Total current liabilities

143.44120.48

Net current liabilities

-25.06-52.88

Net liabilities (capital deficiency)

-20.99-50.10

Gearing (debt/total assets, company definition) (%)

79121

Current ratio (x)

0.830.56

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Cash Flow

MetricFY2021FY2022FY2023FY2024FY2025

Capex PPE additions (HKD Mn)

0.360.630.190.26—

Right-of-use asset additions (HKD Mn)

6.107.546.987.10—

Dividends paid (HKD Mn)

00000

Share buybacks (HKD Mn)

00000

Change in cash (HKD Mn)

—-23.16-2.43-4.72-0.52

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2021FY2022FY2023FY2024FY2025

ROE on average equity (%)

—-32.7-188.1——

ROA on average assets (%)

—-18.0-61.5-29.6-2.1

ROIC pre-tax EBIT on closing invested capital (%)

-38.6-21.2-124.5-41.9—

Current ratio (x)

1.693.680.981.550.83

Debt to equity (x)

0.440.7422.95——

Interest coverage EBIT to finance costs (x)

-14.7-6.7-13.7-3.8—

Asset turnover (x)

—0.470.670.840.81

Inventory days on cost of sales

280.2226.6237.7238.3221.5

Receivable days on health-product revenue

18.216.515.613.18.8

Payable days on cost of sales

81.297.798.786.589.4

Cash conversion cycle (days)

217.2145.4154.6164.9140.9

Region revenue (HKD Mn)

Region revenue (HKD Mn)FY2021FY2022FY2023FY2024FY2025

Hong Kong

169.61141.75146.32113.58—

People's Republic of China

0.470.3100—

Total

170.08142.06146.32113.5899.56

Region growth (%)

Region growth (%)FY2022FY2023FY2024

Hong Kong YoY (%)

-16.43.2-22.4

PRC YoY (%)

-33.9-100.0—

Share Price History

DatePrice / market capSource

Jun 2025

Market cap ≈HK$64.7 M

TipRanks

Aug 2025

Market cap ≈HK$104–117 M

TipRanks

13 Feb 2026

≈HK$0.139 (derived from Eternity stake value HK$23.5 M); market cap HK$107.1 M

Simply Wall St

24 Apr 2026

HK$0.084

ET Net

11 May 2026

HK$0.056

ET Net

13 Jul 2026

HK$0.056

ET Net

27 Jul 2026

Market cap HK$46.2 M; 1-year -37%; 6-month -64.2%

MarketInOut

5 Aug 2026

Placing price HK$0.07

HKEX announcement

22 Sep 2026

5:1 consolidation; HK$0.056 ≈ HK$0.28 per consolidated share equivalent

Derived

Share price performance (%)

1-year

3-year

China Healthwise (to 27 Jul 2026)

-37—

Valuation Snapshot

MultipleValueBasis

Market cap (HKD Mn)

51.8

924.57 M shares × HK$0.056

Enterprise value (HKD Mn)

≈138

  • debt 88.0 + leases 6.6 − cash 8.6 (30 Jun 2026); before HK$10.8 M placing proceeds

P/E

n/m

Losses

EV/EBITDA

n/m

Negative/undisclosed EBITDA (vendor EV/EBITDA 8.96x is not reconciled)

EV/Sales (FY2025)

≈1.4x

EV / HK$99.6 M

P/B

n/m

Negative book value

Capital Instruments

InstrumentPrincipal / carrying (HKD Mn)CouponMaturitySecurity

2024 straight bonds

55.5 principal / 53.69 carrying

8% (15% effective)

30 Dec 2026

100% share pledge over a subsidiary

2024 convertible bonds

16.8 principal / 16.10 carrying

6% (15% effective); conversion HK$0.088 pre-consolidation

30 Dec 2026

Same pledge

Other loan (finance company)

15.8112%

Repayable on demand

Share charge over subsidiary; Company guarantee

Margin loans

2.42

8%–10%

On demand

Listed equities (HK$9.79 M)

Lease liabilities

6.58 (4.82 current)

—

Store leases

—

Total interest-bearing (excl leases)

88.02———

Analyst Conclusions

Management guidance

No numerical guidance. Management expects the retail environment to remain "challenging" (weak local consumption, competition, rising costs), the money-lending environment to remain "challenging and difficult", and will continue cost control, channel expansion, portfolio realisation and negotiations with the bondholder and finance company to renew facilities (H1 2026 interim).

Consensus

No sell-side coverage (0 analysts per Simply Wall St). Consensus growth expectations: not available.

Bull case

  1. Recovery optionality on a fully written-down loan book. HK$296.7 M of gross stage 3 loans carry zero net value; the Customer I property proposal and ongoing partial repayments mean every recovery dollar is pure upside to equity (FY2025 net ECL reversal was HK$3.73 M).

  2. The retail engine is closer to breakeven than headline losses suggest. Goods gross margin is 34% and segment loss was only HK$3.1 M in H1 2026 (a seasonally weak half); with bond interest removed, the operating business could self-fund.

  3. Cheap brand. An EV of roughly HK$140 M for a 49-year-old heritage brand with ~HK$100 M revenue (≈1.4x sales) could attract a strategic acquirer, especially if a debt restructuring transfers the brand to a cleaner vehicle.

Bear case

  1. Maturity wall. HK$72.3 M of bond principal plus a HK$15.8 M on-demand loan versus ≈HK$19 M of cash (incl. placing) — refinancing, conversion or enforcement is unavoidable before 30 Dec 2026.

  2. Secured creditors sit ahead of shareholders on the only valuable asset. Both the bonds and the 12% loan are secured on subsidiary shares; enforcement could leave the listed shell with negligible assets.

  3. Structural decline and dilution. Product revenue has fallen ~23% from FY2023 to FY2025 and kept falling in H1 2026, while equity holders have already absorbed a 20% placing and face CB conversion dilution.

Catalysts and monitorables (next 12 months)

  • Outcome of negotiations on the 2024 Bonds before 30 Dec 2026 (extension, conversion, partial repayment or default).

  • Any demand on the HK$15.8 M other loan.

  • Completion of the Customer I asset-for-debt transfer (Guangzhou properties).

  • FY2026 results (expected March 2027): auditor opinion — risk of escalation from emphasis of matter to disclaimer.

  • Winter/Chinese New Year 2027 trading (inventory build funding).

  • Further equity raises after consolidation; resumption of normal trading on counter 0348 after parallel trading.

  • HKEX scrutiny of sufficiency of operations / financial position.

  • Changes in Eternity Investment's stake or support.

Analyst verdict

China Healthwise is not, at present, an operating-company investment case; it is a credit event in waiting attached to a respectable but shrinking heritage retailer. The core business, Nam Pei Hong, is genuinely viable at the gross-profit level — goods margins of 33%–34% have held through a severe Hong Kong consumption downturn, and management has cut G&A by more than 40% since FY2022. But the listed parent spent FY2018–FY2023 deploying capital into an unsecured money-lending book that has proved almost entirely unrecoverable (97% credit-impaired), and into a listed-equity portfolio that has delivered more volatility than return. The result is a capital deficiency of HK$50 million, net current liabilities of HK$53 million, and HK$72 million of secured bond principal maturing on 30 December 2026 against roughly HK$19 million of cash after the August placing.

The FY2025 "near-breakeven" result was an artefact of a HK$24.6 million unrealised equity gain that reversed in the first half of 2026; investors should anchor on the H1 2026 loss of HK$29 million and the 121% debt-to-assets gearing. The August 2026 placing and share consolidation are classic pre-restructuring housekeeping rather than evidence of a turnaround. The decisive variables over the next three months are entirely on the liability side: whether the bondholder extends or converts, and whether secured creditors choose to enforce over the subsidiary that owns the brand.

Equity value therefore depends on negotiated outcomes that are not publicly visible. Upside exists — recoveries on written-off loans and a strategic sale of the Nam Pei Hong brand could each be material relative to a ~HK$50 million market capitalisation — but the probability-weighted outcome skews toward further dilution or loss of control of the operating subsidiary. We would classify the shares as highly speculative.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleTenure / appointmentBackground (as disclosed or reported)Birth year

Lei Hong Wai (李雄偉)

Chairman, executive director; designated investment director

Chairman since at least 2016/17

—

1968 (vendor)

Cheung Kwok Wai Elton (張國偉)

Vice Chairman, executive director; designated investment director

ED since 28 Oct 2019

HKICPA (vendor); Eternity-nominated director; over 20 years' experience

1966 (vendor)

Leung Alex (梁奕曦)

Executive director

Since at least 2019

Not detailed in sources reviewed

1979 (vendor)

Lo Ming Wan (勞明韵)

Executive director and Company Secretary

Since at least 2019

Not detailed in sources reviewed

1986 (vendor)

Yuan Huixia (袁輝霞)

Executive director

Since at least 2019

Not detailed in sources reviewed

1981 (vendor)

—

Independent non-executive director; audit and nomination committees

Since 31 Oct 2025

20+ years in paper, packaging and printing; INED of Global Mastermind Holdings (8063) and Walnut Capital (905); fee HK$120,000 p.a.

—

Lai Hok Lim (黎學廉)

INED; audit committee

Since at least 2019

Not detailed

—

Tsang Chin Pang (曾展鵬)

INED

—

Not detailed

—

“—” = not publicly disclosed.

Board & Management Changes

DateChangeContext

30 Sep 2024

Tse Chi Keung (ED) resigned

Cost reduction phase

—

Wong Tak Chuen (INED, audit committee chair) left; Tsang Chin Pang joined

Board refresh

27 Jan 2025

Yang Qiangsheng appointed ED (holds 38.0 M pre-consolidation shares, 4.93% pre-subscription)

Shareholder-director

—

Lien Wai Hung (INED) departed

Left the board below required INED numbers

31 Oct 2025

Yang Qiangsheng resigned (personal commitments, no disagreement); Fung Wai Ching appointed INED

Re-compliance with Listing Rules on INED numbers

Directors' Remuneration

Directors' emoluments (HKD Mn)FY2021FY2022FY2023FY2024

Total directors' emoluments

15.6120.1619.069.09

Employee costs excluding directors

21.8521.5823.3619.88

Major Shareholders

HolderShares (pre-consolidation)% pre-subscription (770.48 M)% post-subscription (924.57 M, derived)

Eternity Investment Limited (0764.HK)

169,042,82421.9418.28
—154,090,000—16.67

Yang Qiangsheng (former ED)

38,000,0004.934.11

Lei Hong Wai (Chairman)

18,663,6362.422.02

Public float (31 Dec 2025, per Annual Report 2025)

—70.7—

Competitive Landscape

Key Competitors

CompetitorSegment overlapListingPositioning vs Nam Pei Hong

Beijing Tong Ren Tang Chinese Medicine (3613.HK)

TCM products, tonics, HK retail

HKEX

Far larger, manufacturer-brand owner with proprietary medicines; HK$1,513 M FY2025 revenue

Eu Yan Sang

TCM, bird's nest, ginseng retail in HK/SE Asia

Private (delisted from SGX)

Dominant HK TCM retail chain; brand and scale advantage

Wai Yuen Tong Medicine (0897.HK)

TCM products and retail

HKEX

—

Hung Fook Tong Group (1446.HK)

Herbal drinks and health foods retail

HKEX

—

Po Sum On, Shiu Fung Hong, and other HK ginseng/dried-seafood houses

Ginseng, dried seafood

Mostly private

Similar heritage merchant model

Sheung Wan / Des Voeux Road West dried-seafood merchants

Dried seafood, Sum Yung

Private, fragmented

Price competition at wholesale/retail

Watsons, Mannings (HK health and beauty chains)

Packaged supplements, health foods

Parent-listed (CK Hutchison; Dairy Farm)

Massive footprint in convenience health products

HKTVmall third-party merchants

Online tonics and supplements

—

Price transparency

Shenzhen/Mainland retailers and e-commerce (Tmall, JD Health)

All categories

Various

Absorb northbound HK consumer spending

Hong Kong licensed money lenders (e.g., listed finance subsidiaries)

Money lending

Various

China Healthwise effectively exited new lending

Peer Comparison FY2025

MetricChina Healthwise FY2025Beijing Tong Ren Tang CM FY2025

Revenue (HKD Mn)

99.561,513

Revenue growth (%)

-12.3-6.1

Gross margin (%)

33.661.2

Net margin (%)

-2.626.2

R&D intensity (%)

0—

Company Snapshot

$12.8M

Revenue

70

Employees

1997

Founded

Grand Cayman, Cayman Islands

Headquarters

SWOT Analysis

Strengths

  • Heritage brand: Nam Pei Hong trading since 1977, stated as highly recognised in Hong Kong and southern Mainland China (FY2024 results).
  • Stable goods margin: derived goods gross margin 30.7% (FY2021) → 33.4% (FY2025) → 34.0% (H1 2026) despite falling volumes.
  • Cost discipline demonstrated: G&A down from HK$38.3 M (FY2022) to HK$21.6 M (FY2025); H1 2026 retail segment loss narrowed to HK$3.1 M from HK$4.4 M.
  • Diversified channel mix: FY2022 direct-sales events (HK$41.2 M) and internet (HK$12.5 M) together 42% of product revenue, reducing reliance on shops.
  • Product-mix agility: sea cucumber sales +28% in FY2024; bird's nest, wild cordyceps, Japanese stichopus +4%–16% in H1 2026 while high-end lines fell.
  • Improving working capital efficiency: receivable days fell from 18.2 (FY2021) to 8.8 (FY2025); cash conversion cycle from 217 to 141 days (derived).

Weaknesses

  • Capital deficiency: net liabilities HK$50.1 M at 30 Jun 2026 (HK$21.0 M at end-2025).
  • Going-concern material uncertainty: auditor emphasis in FY2023, FY2024 and FY2025 opinions.
  • Failed loan book: HK$296.7 M of HK$305.7 M gross loans credit-impaired (97%); cumulative ECL allowance HK$297.0 M.
  • Liquidity mismatch: current liabilities HK$120.5 M vs current assets HK$67.6 M (current ratio 0.56) at 30 Jun 2026.
  • Revenue erosion: group revenue down from HK$170.1 M (FY2021) to HK$99.6 M (FY2025), -12.5% CAGR; H1 2026 health products -6%.
  • Governance gaps: no D&O insurance (CG Code C.1.7 deviation); temporary INED shortfall in 2025; connected-party revolving loan to substantial shareholder's group.

Opportunities

  • Customer I recovery: third-party proposal to settle via transfer of Guangzhou properties (H1 2026) could crystallise value from a fully provided loan.
  • Partial recoveries on stage 3 loans: Customers E, F, G, J, K have made partial payments; Customer L on a 5-year instalment plan from Jul 2024 — any recovery flows directly to profit as ECL reversal (FY2025 net reversal HK$3.73 M).
  • Corporate staff-purchase and B2B channels with banks and insurers (H1 2026 plan).
  • Mainland social commerce (Xiaohongshu/Weimob, Tmall Global) to reach younger buyers.
  • Medicine-food homology policy supports convenient health-food formats where the Company is building range.
  • Brand monetisation: a heritage brand could attract a strategic buyer or licensee if separated from the parent's liabilities.

Threats

  • Bond maturity: HK$72.3 M principal of 2024 Bonds due 30 Dec 2026 vs HK$8.55 M cash at 30 Jun 2026 plus HK$10.8 M placing proceeds.
  • Security enforcement: 2024 Bonds secured by 100% share pledge over a subsidiary; other loan (HK$15.8 M, 12%, on demand) secured by subsidiary share charge — enforcement could strip the operating business.
  • Northbound consumption shift cited every year FY2023–H1 2026 as depressing local sales.
  • Mainland customs tightening on high-end health products carried by travellers (H1 2026).
  • Market-value-driven forced selling: January 2026 forced Yunfeng sale shows vulnerability to margin calls; remaining portfolio only HK$14.1 M.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Apr 2025Annual Report 2024 published; INED and ED changes recordedFormal disclosure of going-concern uncertainty and net liabilities HK$18.4 M
May–Jun 2025AGM notice: re-election of directors, auditor re-appointment, general mandatesRoutine
18 Jun 2025AGM: all resolutions passedMandates renewed
Aug 2025Board meeting scheduled for 27 Aug 2025Routine
Aug 2025Positive profit alert: H1 2025 profit HK$0.1–2.0 M vs HK$29 M lossFirst sign of stabilisation
27 Aug 2025H1 2025 results: profit HK$1.42 M; revenue HK$51.1 MDriven by HK$12.4 M FV gain and HK$3.1 M ECL reversal
–INED departure leaves board below Listing Rule minimumGovernance lapse
31 Oct 2025Yang Qiangsheng resigns as ED; Fung Wai Ching appointed INEDRe-compliance with INED rules
31 Dec 2025Store count reduced to 9 from 10Footprint rationalisation
Jan 2026Forced sale of 2,646,000 Yunfeng Financial shares (≈HK$9.2 M)Evidence of margin-call liquidity stress
Feb 2026Market cap ≈HK$107 M (vendor)Pre-results peak
20 Mar 2026HK$9 M revolving loan to Eternity group extended to Mar 2027 at 10%Connected transaction; scrutiny
27 Mar 2026FY2025 results: revenue HK$99.6 M (-12.3%); loss HK$2.61 M; net liabilities HK$21.0 M; finance costs +66.7%Loss narrows on non-cash gains; liquidity worsens
Apr 2026Share price falls to HK$0.084 (24 Apr)Market reaction to liquidity disclosures
29–30 Apr 2026Annual Report 2025 published with formal investment policyGovernance enhancement
May 2026Share price HK$0.056 (11 May)-60% vs Feb 2026
25 Jun 2026AGM; 20% general issuance mandate grantedEnables placing
27 Jul 2026Vendor market cap HK$46.2 M; 6-month price change -64%Distress pricing
5 Aug 2026Subscription agreement: 154.09 M shares at HK$0.07 (≈HK$10.8 M)Dilutive emergency equity
13 Aug 20265-into-1 share consolidation proposedAddress low share price / trading-band requirements
Aug 2026Board meeting date for interim results set (vendor showed 20 Aug; results released 27 Aug)Routine
27 Aug 2026Subscription completed; issued shares 924.57 MCash +HK$10.8 M
27 Aug 2026H1 2026 results: revenue HK$36.5 M (-29%); loss HK$29.1 M; net liabilities HK$50.1 M; gearing 121%Reversal of FY2025 recovery
27 Aug 2026Disclosure that a third party proposes to acquire Customer I's loan via transfer of Guangzhou propertiesPossible non-cash recovery
Late Aug–Sep 2026Circular and EGM for share consolidation (EGM approval inferred from effectiveness)Corporate action
22 Sep 2026Share consolidation effective; temporary counter 2931Share base ≈184.9 M
By 30 Dec 2026 (pending)2024 Bonds maturity HK$72.3 MCritical liquidity event

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

6 charts
Income Statement: Revenue & Gross Profit: Revenue fell from HKD 170.1 Mn in FY2021 to HKD 99.6 Mn in FY2025.
China Healthwise Holdings Limited — Income Statement: Revenue & Gross Profit
Series (HKD Mn)FY2021FY2022FY2023FY2024FY2025
Revenue170.1142.1146.3113.699.6
Cost of sales79.188.88676.266.1
Gross profit9153.360.337.433.5

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. HKEX — China Healthwise Holdings, Annual Results Announcement FY2024 (31 Mar 2025) (www1.hkexnews.hk)
  2. HKEX — Annual Results Announcement FY2023 (26 Mar 2024) (www1.hkexnews.hk)
  3. HKEX — Annual Results Announcement FY2022 (28 Mar 2023) (www1.hkexnews.hk)
  4. HKEX — Annual Results Announcement FY2021 (28 Mar 2022) (www1.hkexnews.hk)
  5. HKEX — Unaudited Interim Results H1 2026 (27 Aug 2026) (www1.hkexnews.hk)
  6. HKEX — Annual Report 2024 (hkexnews.hk)
  7. HKEX — Annual Report 2016/2017 (name change) (hkexnews.hk)
  8. HKEX — Annual Report 2015/2016 (Haier Healthwise) (hkexnews.hk)
  9. HKEX — Change of financial year end announcement (2 Dec 2019) (www1.hkexnews.hk)
  10. HKEX — Trading arrangement notice, share consolidation (Sep 2026) (hkex.com.hk)
  11. HKEX — AGM notices 2022–2024 (auditor HLB Hodgson Impey Cheng) (www1.hkexnews.hk)
  12. HKEX DI form (Leung Lun, 2015) (di.hkex.com.hk)
  13. Bulletin Express / Tiger Brokers — FY2025 results summary (27 Mar 2026) (itiger.com)
  14. Bulletin Express / Tiger Brokers — Director changes (31 Oct 2025) (itiger.com)
  15. Minichart — Annual Report 2025 summary (30 Apr 2026) (minichart.com.sg)
  16. Webull/PUBT — Subscription announcement (5 Aug 2026) (webull.hk)
  17. TipRanks — H1 2025 results and profit alert (tipranks.com)
  18. TipRanks — Revenue history (tipranks.com)
  19. ET Net — Company profile and quotes (mpf.etnet.com.hk)
  20. Simply Wall St — Ownership (simplywall.st)
  21. MarketInOut — Profile and price performance (27 Jul 2026) (marketinout.com)
  22. Yahoo Finance — Profile and executive compensation (uk.finance.yahoo.com)
  23. moomoo — Listing data and ISIN (moomoo.com)
  24. StockAnalysis — Beijing Tong Ren Tang CM income statement (stockanalysis.com)
  25. Quartr — Beijing Tong Ren Tang CM FY2025 summary (quartr.com)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.